CD19 and B-cell chronic lymphocytic leukemia: Each has been evaluated for time since last division/age and transitioning to a resting state, relative levels of smIgM and smIgD, and the synergistic roles of different activation pathways and co-stimulatory CD19 in determining the CLL phenotypes and kinetics observed.